Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.

@article{Hargreaves2011DevelopmentOA,
  title={Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.},
  author={Richard J. Hargreaves and Juan Camilo Arjona Ferreira and David Hughes and Jos Brands and Jeff Hale and Britta Mattson and Sandy Mills},
  journal={Annals of the New York Academy of Sciences},
  year={2011},
  volume={1222},
  pages={40-8}
}
Chemotherapy can be a life-prolonging treatment for many cancer patients, but it is often associated with profound nausea and vomiting that is so distressing that patients may delay or decline treatment to avoid these side effects. EMEND (aprepitant) is the first and only neurokinin-1 (NK-1) receptor antagonist available on the market for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Aprepitant acts centrally at NK-1 receptors in vomiting centers within… CONTINUE READING